.cancerresearch

The Big picture…

The Big Picture

Australian Cancer Research Foundation

.CANCERRESEARCH is a collaborative initiative facilitated by the Australian Cancer Research Foundation. Its focus is to bring together news, information, and leading opinion on cancer treatment, prevention, diagnosis and cure. We want you to be a part of the .CANCERRESEARCH community...

Please click here to learn more.

Home.

Cancer
Research

HOME.CANCERRESEARCH

Explore our home site for an idea of what .CANCERRESEARCH has to offer.

> Information on different types of cancer
> Cancer research endeavours of the past and near future
> Ways you can get involved

Visit our home site home.cancerresearch

 

New genetic causes of ovarian cancer identified

 
ACRF
ACRF
March 29, 2017

An international collaborative study has confirmed that 30 genetic variants in addition to BRCA1 and BRCA2 increase a woman’s risk of developing ovarian cancer.

The study involved 418 researchers from both the Ovarian Cancer Association Consortium, led by Dr Andrew Berchuck from the United States, and the Consortium of Investigators of Modifiers of BRCA1/2, led by Professor Georgia Chenevix-Trench from QIMR Berghofer Medical Research Institute.

Professor Chenevix-Trench said it was known that a woman’s genetic make-up accounts for about one third of her overall risk of developing ovarian cancer.

“This is the inherited component of the disease risk,” Professor Chenevix-Trench said.

“Inherited faults in genes such as BRCA1 and BRCA2 account for about 40 per cent of that genetic risk. Other variants that are more common in the population (carried by more than one in 100 people) are believed to account for most of the rest of the inherited component of risk.”

Study reveals new genetic variants

Professor Chenevix-Trench said the study investigated the DNA of nearly 100,000 people, including patients with the most common types of ovarian cancer and healthy controls.

“We have identified 12 new genetic variants that increase a woman’s risk of developing the cancer. We have also confirmed that 18 variants that had been previously identified do increase the risk.”

“As a result of this study, we now know about a total of 30 genetic variants in addition to BRCA1 and BRCA2 that increase a woman’s risk of developing ovarian cancer. Together these 30 variants account for another 6.5 per cent of the genetic component of ovarian cancer risk.”

QIMR Berghofer’s Professor Penny Webb said ovarian cancer was a highly complex disease.

“Even the 30 genetic variants that we now know increase risk of developing the disease account for just a small fraction of the inherited component,” she said.

“There are likely to be many more genetic variants involved, each with extremely small effects. Most of these are likely to be common in the population, but some will be rare.”

Professor Susan Ramus from UNSW said while the study had significantly advanced the knowledge of the genetic drivers of ovarian cancer, there was a lot more work to do.

“We really do not understand how these genetic variants affect risk, but with further study they may help us to treat and possibly prevent ovarian cancer” Professor Ramus said.

“This study also highlights that Australia is at the global forefront of genetics research. Thirty-two Australian researchers from eight different institutions contributed to this major, international study. It also involved DNA and lifestyle information from nearly 6,000 Australian women.”

Cancer Australia estimates that in 2017 nearly 1,600 Australian women will be newly diagnosed with ovarian cancer and nearly 1,050 will die from the disease. Only 44 per cent of women who are diagnosed with ovarian cancer will survive for five years.

The findings have been published this week in the journal Nature Genetics.

This article was first published on QIMR Berghofer’s website, image of  Professor Chenevix-Trench courtesy of QIMR Berghofer.

The Australian Cancer Research Foundation has supported cancer research at QIMR Berghofer by providing three grants, totalling AUD$ 6.65 M, for the purchase of cutting edge research equipment and technology.

Subscribe to our newsletter